$NUTX

These Two Healthcare Stocks Are Beating the Sector, They Still Look Cheap

Nutex Health (NUTX) and Elevance Health (ELV) have outperformed the healthcare sector in 2026, with NUTX up 36% and ELV up 11%. NUTX trades at a P/E of 9, while ELV is at 18, both below the sector average of 29.75. NUTX reported strong earnings growth, and ELV reaffirmed its 2026 guidance, highlighting stabilization in its cost structure.

Original reporting
Published Oct 9, 2026, 2:54 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 4:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
These Two Healthcare Stocks Are Beating the Sector, They Still Look Cheap — source image
Decision brief

The 30-second read

$NUTXBullishLow
01

Why it matters

Both stocks are portrayed as undervalued relative to peers, implying possible modest upside, but no new corporate events are disclosed.

02

Market read

Provides a valuation comparison that may prompt re‑rating of the two stocks, but limited trading urgency.

03

What to watch

Potential impact of ongoing healthcare policy changes and payer mix shifts not fully quantified.

Relevance 4/10Novelty 2/10Timing: none

Background

The article is a watch‑list style recap comparing Nutex Health (NUTX) and Elevance Health (ELV) to the broader healthcare sector, using previously released earnings data.

Company-level read

Ticker impact

$NUTXBullishMedium confidence
Context

Nutex Health is highlighted as a cheap, fast‑growing small‑cap hospital operator that has outperformed the healthcare sector YTD.

Expected impact

likely modest upside as investors re‑evaluate valuation gap

Evidence & confidence

No new corporate event; the piece is a recap of prior earnings and guidance, but the cheap valuation may attract fresh buying.

$ELVBullishMedium confidence
Context

Elevance Health is presented as an undervalued large‑cap insurer with solid dividend yield, buybacks and reaffirmed guidance.

Expected impact

potential modest upside from valuation re‑rating

Evidence & confidence

Again, no new corporate action; the article recaps prior results, but the highlighted dividend and buyback may spur incremental buying.

Market effects

The piece suggests the broader healthcare sector may be overvalued relative to these two cheaper peers.

U.S. healthcare equities could see modest re‑rating pressure.

Limited; focus is on U.S. listed health companies.

Counterpoint

Valuation gaps may reflect underlying risk; the cheap multiples could be justified by operational or regulatory headwinds.

Key entities

  • Nutex Health

    Small‑cap hospital operator

  • Elevance Health

    Large‑cap health insurer

Related articles

$ELVMed

Cantor Fitzgerald keeps Elevance stock rating on Medicare concerns

Cantor Fitzgerald maintained an Overweight rating and $450 price target for Elevance Health (ELV) despite a decline in its 2027 Medicare Stars ratings. The firm expects pressure on the stock due to concerns around Medicare Advantage management. Elevance reaffirmed its 2026 earnings guidance, projecting at least $20.10 per diluted share. Analysts have mixed views, with Guggenheim raising its target to $455 and RBC lowering it to $424.

$CNCHigh

ACA fraud crackdown threatens health insurer profits in 2026

Vice President JD Vance announced 760,000 ACA enrollees were dropped due to fraud, with 400,000 under review. Insurers like Centene, Molina, Elevance, and UnitedHealth saw stock declines. Experts warn of squeezed margins in 2026-2027 due to a less healthy risk pool. Premium rates for 2027 are locked, and insurers may push for higher 2028 rates. Brokers, who drive 75% of sign-ups, face new restrictions and potential reputational damage.